🔥🐔 BizChicken 🐔🔥
Companies Similar to PaxMedica, Inc. Common Stock
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Contineum Therapeutics, Inc. Class A Common Stock
PIPE-791
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
Symbol: CTNM
Recent Price: $14.47
Industry: Biotechnology
CEO: Mr. Carmine N. Stengone MBA, MS
Sector: Healthcare
Employees: 31
Address: 10578 Science Center Drive, San Diego, CA 92121
Phone: (858) 333-5280
Leadership
- Carmine Stengone, President and Chief Executive Officer
- Austin Chen, PhD, Senior Vice President, Head of Research
- Beverly Dixon, Senior Director, Quality Assurance
- Kristina Haeckl, Sr. Vice President, Regulatory Affairs
- Daniel Lorrain, PhD, Chief Scientific Officer
- John Healy, General Counsel & Corporate Secretary
- Jon Seiders, PhD, Vice President, CMC
- Jules Lee, Senior Director, Clinical Operations
- Julie Iwashita, Vice President, Clinical Operations
- Karin Stebbins, Vice President, Toxicology
- Michael Mayberry, Vice President, Finance
- Mike Poon, PhD, Vice President, Biology
- Peter Slover, Chief Financial Officer
- Stephen Huhn, MD, Chief Medical Officer & Senior Vice President, Clinical Development
- Tara Vargas, Senior Director, Project Management
- Thomas O. Schrader, PhD, Senior Director, Chemistry
- Varsha Dourado, Vice President, Business Development
Last updated: 2024-12-31
Passage Bio, Inc.
PBGM01, PBFT02, PBKR03, PBML04, PBAL05, PBCM06
Passage Bio, Inc. develops transformative therapies for central nervous system diseases using proprietary genetic medicine technologies to deliver functional genes for the treatment of various disorders.
Symbol: PASG
Recent Price: $0.67
Industry: Biotechnology
CEO: Dr. William Chou M.D.
Sector: Healthcare
Employees: 58
Address: One Commerce Square, Philadelphia, PA 19103
Phone: 267 866 0311
Leadership
- William Chou, MD, President and Chief Executive Officer
- Kathleen Borthwick, Chief Financial Officer
- Sue Browne, PhD, Chief Scientific Officer
- Edgar B. (Chip) Cale, General Counsel and Corporate Secretary
- Eden Fucci, SVP Technical Operations
- Stuart Henderson, Chief Business Officer
- Karl Whitney, PhD, SVP Global Regulatory Affairs
- James M. Wilson, MD, PhD, Scientific Advisor
- Maxine Gowen, PhD, Chairwoman
- Athena Countouriotis, MD,
- Derrell D. Porter, MD,
- Dolan Sondhi, PhD,
- Sandip Kapadia,
- Tom Kassberg,
- Saqib Islam,
- Samiah Al-Zaidy, MD, Vice President, Clinical Development
- Andrea Campanile, Vice President, Clinical Operations
Last updated: 2024-12-31
Syndax Pharmaceuticals, Inc.
SNDX-5613, SNDX-6352 (axatilimab), Entinostat
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.
Symbol: SNDX
Recent Price: $12.52
Industry: Biotechnology
CEO: Mr. Michael A. Metzger M.B.A.
Sector: Healthcare
Employees: 184
Address: 35 Gatehouse Drive, Waltham, MA 02451
Phone: 781 419 1400
Last updated: 2024-12-31
Pyxis Oncology, Inc.
PYX-106, PYX-102, PYX-201, PYX-202, PYX-203
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, focuses on developing therapies to treat various cancers through immune-oncology and antibody drug conjugate product candidates.
Symbol: PYXS
Recent Price: $1.56
Industry: Biotechnology
CEO: Dr. Lara S. Sullivan M.D., MBA
Sector: Healthcare
Employees: 55
Address: 35 Cambridgepark Drive, Cambridge, MA 02140
Phone: 617 221 9059
Last updated: 2024-12-31
Tenax Therapeutics, Inc.
TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)
Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.
Symbol: TENX
Recent Price: $6.55
Industry: Biotechnology
CEO: Mr. Christopher T. Giordano
Sector: Healthcare
Employees: 5
Address: ONE Copley Parkway, Morrisville, NC 27560
Phone: 919 855 2100
Last updated: 2024-12-31
Vaccinex, Inc.
pepinemab
Vaccinex, Inc., a clinical-stage biotechnology company, focuses on developing targeted biotherapeutics for cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical trials for multiple serious conditions.
Contact | Contact | Careers | About | Careers | About | About | About | About | About | News | Events | About | About | ESG | About | About | About | About | About
Symbol: VCNX
Recent Price: $1.11
Industry: Biotechnology
CEO: Dr. Maurice Zauderer Ph.D.
Sector: Healthcare
Employees: 37
Address: 1895 Mount Hope Avenue, Rochester, NY 14620
Phone: 585 271 2700
Last updated: 2024-12-31
Tonix Pharmaceuticals Holding Corp.
TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.
Symbol: TNXP
Recent Price: $0.36
Industry: Biotechnology
CEO: Dr. Seth Lederman M.D.
Sector: Healthcare
Employees: 103
Address: 26 Main Street, Chatham, NJ 07928
Phone: 862 799 8599
Last updated: 2024-12-31
Pfizer Inc.
biopharmaceutical products
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide, offering medicines and vaccines across various therapeutic areas.
About | About | About | About | About | About | About | About | About | About | DEI | ESG | About | Safety | About | ESG | About | About | About | About | About | About | About | About | About | About | History | About | About | About | About | About | About | News | About | Directors | Contact | Careers | Careers | Careers | Careers | Careers | Careers | DEI | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About | About | About | About
Symbol: PFE
Recent Price: $26.42
Industry: Drug Manufacturers - General
CEO: Dr. Albert Bourla D.V.M., Ph.D.
Sector: Healthcare
Employees: 88000
Address: 235 East 42nd Street, New York, NY 10017
Phone: 212 733 2323
Last updated: 2024-12-31
Axsome Therapeutics, Inc.
AXS-05, AXS-07, AXS-12, AXS-14
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.
About | Leadership | Directors | About | About | About | About | About | About | Contact | Careers | Careers | About | About
Symbol: AXSM
Recent Price: $84.78
Industry: Biotechnology
CEO: Dr. Herriot Tabuteau M.D.
Sector: Healthcare
Employees: 589
Address: 22 Cortlandt Street, New York, NY 10007
Phone: 212 332 3241
Leadership
- Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
- Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
- Mark Jacobson, MA, CHIEF OPERATING OFFICER
- Hunter Murdock, Esq., GENERAL COUNSEL
- ari Maizel, Executive Vice President, Head of Commercial
- Mark Coleman, MD, DIRECTOR
- Roger Jeffs, PhD, DIRECTOR
- Susan Mahony, PhD, MBA, DIRECTOR
- Mark Saad, DIRECTOR
Last updated: 2024-12-31
Compass Therapeutics, Inc.
CTX-009, CTX-471, CTX-8371
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.
Symbol: CMPX
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.
Sector: Healthcare
Employees: 32
Address: 80 Guest Street, Boston, MA 02135
Phone: 617 500 8099
Last updated: 2024-12-31
Cue Biopharma, Inc.
CUE-101
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing biologic drugs to modulate the human immune system for treating cancers, chronic infectious diseases, and autoimmune disorders.
About | Leadership | About | Directors | About | Contact | About | About | About | Careers | Careers | Careers | Careers | Careers | About
Symbol: CUE
Recent Price: $1.02
Industry: Biotechnology
CEO: Mr. Daniel R. Passeri J.D., M.Sc.
Sector: Healthcare
Employees: 53
Address: 21 Erie Street, Cambridge, MA 02139
Phone: 617 949 2680
Leadership
- Dan Passeri, Chief Executive Officer
- Anish Suri, President and Chief Scientific Officer
- Lucinda Warren, Chief Business Officer
- Matteo Levisetti, Chief Medical Officer
- Kerri-Ann Millar, Chief Financial Officer
- Colin Sandercock, Senior Vice President and General Counsel
- Frank Morich, M.D., Ph.D., Chairman of the Board
- Dan Passeri, M.Sc., J.D., Chief Executive Officer
- Peter Kiener, D.Phil.,
- Fred Driscoll,
- Patrick Verheyen,
- Pamela D. Garzone, Ph.D.,
Last updated: 2024-12-31
Lumos Pharma, Inc.
LUM-201
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for rare diseases, with its lead candidate LUM-201 in a Phase 2 trial for pediatric growth hormone deficiency.
Symbol: LUMO
Recent Price: $4.34
Industry: Biotechnology
CEO: Mr. Richard J. Hawkins
Sector: Healthcare
Employees: 33
Address: 4200 Marathon Boulevard, Austin, TX 78756
Phone: 512 215 2630
Last updated: 2024-12-31
Lexeo Therapeutics, Inc. Common Stock
LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004
Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.
Symbol: LXEO
Recent Price: $6.54
Industry: Biotechnology
CEO: Mr. R. Nolan Townsend
Sector: Healthcare
Employees: 69
Address: 345 Park Avenue South, New York, null 10010
Phone: 212-547-9879
Last updated: 2024-12-31
Nurix Therapeutics, Inc.
NX-2127, NX-5948, NX-1607, NX-0255
Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.
Symbol: NRIX
Recent Price: $18.64
Industry: Biotechnology
CEO: Dr. Arthur T. Sands M.D., Ph.D.
Sector: Healthcare
Employees: 284
Address: 1700 Owens Street, San Francisco, CA 94158
Phone: 415 660 5320
Last updated: 2024-12-31
PTC Therapeutics, Inc.
Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.
About | History | Leadership | About | Contact | Careers | Careers | Jobs | About | About | About | About
Symbol: PTCT
Recent Price: $45.77
Industry: Biotechnology
CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Sector: Healthcare
Employees: 988
Address: 100 Corporate Court, South Plainfield, NJ 07080
Phone: 908 222 7000
Leadership
- Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
- Neil Almstead, Ph.D., Chief Technical Operations Officer
- John Baird, Ph.D., Chief of Staff to the CEO
- Mark E. Boulding, Executive Vice President and Chief Legal Officer
- Lee Golden, M.D., Chief Medical Officer
- Pierre Gravier, Chief Financial Officer
- Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
- Linda Montella-Carter, Senior Vice President and Chief Information Officer
- Eric Pauwels, Chief Business Officer
- Hege Sollie-Zetlmayer, Chief Human Resources Officer
- Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
- Michael Schmertzler, Chairman
- William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
- Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
- Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
- Emma Reeve, Independent Board Director
- Mary Smith, The VENG Group
- David P. Southwell, Former CEO, TScan Therapeutics
- Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
- Alethia Young, Chief Financial Officer, Bicycle Therapeutics
- Jerome B. Zeldis, M.D., Ph.D., Independent Board Director
Last updated: 2024-12-31
X4 Pharmaceuticals, Inc.
mavorixafor
X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases, with its lead product mavorixafor in advanced clinical trials.
Symbol: XFOR
Recent Price: $0.81
Industry: Biotechnology
CEO: Dr. Paula Ragan Ph.D.
Sector: Healthcare
Employees: 127
Address: 61 North Beacon Street, Boston, MA 02134
Phone: 857 529 8300
Last updated: 2024-12-31
Immix Biopharma, Inc.
IMX-110, IMX-111, IMX-120
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.
Symbol: IMMX
Recent Price: $2.36
Industry: Biotechnology
CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Sector: Healthcare
Employees: 14
Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064
Phone: 310 651 8041
Last updated: 2024-12-31
Nuvectis Pharma, Inc.
NXP800, NXP900
Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.
Symbol: NVCT
Recent Price: $5.14
Industry: Biotechnology
CEO: Mr. Ron Bentsur M.B.A.
Sector: Healthcare
Employees: 13
Address: 1 Bridge Plaza, Fort Lee, NJ 07024
Phone: 201 614 3150
Last updated: 2024-12-31
Praxis Precision Medicines, Inc.
PRAX-114, PRAX-944, PRAX-562, PRAX-222, KCNT1 program
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal imbalance, with multiple products in different stages of clinical trials.
Symbol: PRAX
Recent Price: $76.26
Industry: Biotechnology
CEO: Mr. Marcio Silva De'Souza M.B.A.
Sector: Healthcare
Employees: 82
Address: 99 High Street, Boston, MA 02110
Phone: 617 300 8460
Last updated: 2024-12-31
PaxMedica, Inc. Common Stock
PAX-101
Pax Medica, Inc., is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for treating intractable neurologic disorders. Their lead product, PAX-101, is an intravenous formulation of suramin for indications such as autism spectrum disorder and chronic fatigue syndrome.
Symbol: PXMD
Recent Price: $0.06
Industry: Biotechnology
CEO: Mr. Howard J. Weisman
Sector: Healthcare
Employees: 6
Address: 303 South Broadway, Tarrytown, NY 10591
Phone: 914-987-2876
Last updated: 2024-12-31